Logo - P&S Intelligence
  • Home
  • Report Store
    • Report Store
      • Consumer Products
      • Life Sciences
      • ICT and Media
      • Semiconductor and Electronics
      • Chemicals and Materials
      • Automotive and Transportation
      • Power and Energy
      • Heating & Cooling
      • Aerospace & Defense
      • Construction & Heavy Machinery
    • Back
  • Services
  • Knowledge Center
    • Knowledge Center
      • Press Journals
      • Blogs
      • Case Studies
    • Back
  • About Us
  • Contact Us
Hospital-Acquired Infection Diagnostics Market

Available Format: PDF  |  Pages:  176

  • Get Free Sample
  • Make an Inquiry
  • Home
  • Life Sciences
  • Hospital-Acquired Infection Diagnostics Market

Hospital-Acquired Infection (HAI) Diagnostics Market by Product (Reagents and Consumables, Instruments), by Test Type (Immunoassay, Molecular Diagnostics, Urinalysis), by Application (Drug-Resistance, Disease), by Infection Type (UTIs, Surgical Site, Bloodstream, Gastrointestinal Hospital Acquired Pneumonia), by End User (Hospitals, Clinics, ASCs), by Geography (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Japan, China, Australia, South Korea, India, Brazil, Saudi Arabia, South Africa), Global Market Size, Share, Development, Growth, and Demand Forecast, 2016-2023

  • Published: July 2024
  • Report Code: 11385
  • Available Format: PDF
  • Pages: 176
  • Report Description
  • Table of Contents
  • Market Segmentation
  • Request Free Sample

Chapter 1. Research Background

1.1 Research Objectives

1.2 Market Definition

1.3 Research Scope

1.3.1 Market Segmentation by Product

1.3.2 Market Segmentation by Test Type

1.3.3 Market Segmentation by Application

1.3.4 Market Segmentation by Infection Type

1.3.5 Market Segmentation by End User

1.3.6 Market Segmentation by Geography

1.3.7 Analysis Period

1.3.8 Market Data Reporting Unit

1.3.8.1 Value

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By region

2.2.1.2 By industry participant

2.2.1.3 By company type

2.3 Market Size Estimation

2.4 Data Triangulation

2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1 Definition of Market Segments

4.1.1 By Product

4.1.1.1 Reagents & consumables

4.1.1.2 Instruments

4.1.2 By Test Type

4.1.2.1 Immunoassay

4.1.2.2 Molecular diagnostics

4.1.2.3 Urinalysis

4.1.3 By Application

4.1.3.1 Drug-resistance testing

4.1.3.2 Disease testing

4.1.4 By Infection Type

4.1.4.1 Urinary tract infections (UTI)

4.1.4.2 Surgical site infections

4.1.4.3 Bloodstream infections

4.1.4.4 Gastrointestinal infections

4.1.4.5 Hospital acquired pneumonia

4.1.4.6 Others

4.1.5 By End User

4.1.5.1 Hospitals

4.1.5.2 Clinics

4.1.5.3 Ambulatory surgery centres (ASCs)

4.1.5.4 Others

4.2 Market Dynamics

4.2.1 Drivers

4.2.1.1 Growing geriatric population

4.2.1.2 Rising demand for HAIs diagnostics in emerging economies

4.2.1.3 Development of technologically advanced products

4.2.1.4 Impact analysis of drivers on market forecast

4.2.2 Restraints

4.2.2.1 Low prevalence of nosocomial infections in developed nations

4.2.2.2 Lack of awareness about HAIs

4.2.2.3 Impact analysis of restraints on market forecast

4.2.3 Opportunities

4.2.3.1 Rise in awareness initiatives by various organizations

4.3 Porter’s Five Forces Analysis

4.3.1 Bargaining Power of Buyers

4.3.2 Bargaining Power of Suppliers

4.3.3 Intensity of Rivalry

4.3.4 Threat of New Entrants

4.3.5 Threat of Substitutes

Chapter 5. Global Market Size and Forecast

5.1 By Product

5.2 By Test Type

5.3 By Application

5.4 By Infection Type

5.5 By End User

5.6 By Region

Chapter 6. North America Market Size and Forecast

6.1 By Product

6.2 By Test Type

6.3 By Application

6.4 By Infection Type

6.5 By End User

6.6 By Country

6.6.1 U.S. Hospital-Acquired Infection Diagnostics Market

6.6.1.1 By product

6.6.1.2 By test type

6.6.1.3 By application

6.6.1.4 By infection type

6.6.1.5 By end user

6.6.2 Canada Hospital-Acquired Infection Diagnostics Market

6.6.2.1 By product

6.6.2.2 By test type

6.6.2.3 By application

6.6.2.4 By infection type

6.6.2.5 By end user

6.6.3 Mexico Hospital-Acquired Infection Diagnostics Market

6.6.3.1 By product

6.6.3.2 By test type

6.6.3.3 By application

6.6.3.4 By infection type

6.6.3.5 By end user

Chapter 7. Europe Market Size and Forecast

7.1 By Product

7.2 By Test Type

7.3 By Application

7.4 By Infection Type

7.5 By End User

7.6 By Country

7.6.1 Germany Hospital-Acquired Infection Diagnostics Market

7.6.1.1 By product

7.6.1.2 By test type

7.6.1.3 By application

7.6.1.4 By infection type

7.6.1.5 By end user

7.6.2 France Hospital-Acquired Infection Diagnostics Market

7.6.2.1 By product

7.6.2.2 By test type

7.6.2.3 By application

7.6.2.4 By infection type

7.6.2.5 By end user

7.6.3 U.K. Hospital-Acquired Infection Diagnostics Market

7.6.3.1 By product

7.6.3.2 By test type

7.6.3.3 By application

7.6.3.4 By infection type

7.6.3.5 By end user

7.6.4 Italy Hospital-Acquired Infection Diagnostics Market

7.6.4.1 By product

7.6.4.2 By test type

7.6.4.3 By application

7.6.4.4 By infection type

7.6.4.5 By end user

7.6.5 Spain Hospital-Acquired Infection Diagnostics Market

7.6.5.1 By product

7.6.5.2 By test type

7.6.5.3 By application

7.6.5.4 By infection type

7.6.5.5 By end user

Chapter 8. APAC Market Size and Forecast

8.1 By Product

8.2 By Test Type

8.3 By Application

8.4 By Infection Type

8.5 By End User

8.6 By Country

8.6.1 Japan Hospital-Acquired Infection Diagnostics Market

8.6.1.1 By product

8.6.1.2 By test type

8.6.1.3 By application

8.6.1.4 By infection type

8.6.1.5 By end user

8.6.2 China Hospital-Acquired Infection Diagnostics Market

8.6.2.1 By product

8.6.2.2 By test type

8.6.2.3 By application

8.6.2.4 By infection type

8.6.2.5 By end user

8.6.3 Australia Hospital-Acquired Infection Diagnostics Market

8.6.3.1 By product

8.6.3.2 By test type

8.6.3.3 By application

8.6.3.4 By infection type

8.6.3.5 By end user

8.6.4 South Korea Hospital-Acquired Infection Diagnostics Market

8.6.4.1 By product

8.6.4.2 By test type

8.6.4.3 By application

8.6.4.4 By infection type

8.6.4.5 By end user

8.6.5 India Hospital-Acquired Infection Diagnostics Market

8.6.5.1 By product

8.6.5.2 By test type

8.6.5.3 By application

8.6.5.4 By infection type

8.6.5.5 By end user

Chapter 9. LAMEA Market Size and Forecast

9.1 By Product

9.2 By Test Type

9.3 By Application

9.4 By Infection Type

9.5 By End User

9.6 By Country

9.6.1 Brazil Hospital-Acquired Infection Diagnostics Market

9.6.1.1 By product

9.6.1.2 By test type

9.6.1.3 By application

9.6.1.4 By infection type

9.6.1.5 By end user

9.6.2 Saudi Arabia Hospital-Acquired Infection Diagnostics Market

9.6.2.1 By product

9.6.2.2 By test type

9.6.2.3 By application

9.6.2.4 By infection type

9.6.2.5 By end user

9.6.3 South Africa Hospital-Acquired Infection Diagnostics Market

9.6.3.1 By product

9.6.3.2 By test type

9.6.3.3 By application

9.6.3.4 By infection type

9.6.3.5 By end user

Chapter 10. Competitive Landscape

10.1 Market Share Analysis of Key Players

10.2 Global Strategic Developments of Key Players

10.2.1 Mergers and Acquisitions

10.2.2 Product Launch and Approvals

10.2.3 Partnerships

Chapter 11. Company Profiles

11.1 Abbott Laboratories

11.1.1 Business Overview

11.1.2 Product and Service Offerings

11.2 AstraZeneca plc

11.2.1 Business Overview

11.2.2 Product and Service Offerings

11.3 Bayer AG

11.3.1 Business Overview

11.3.2 Product and Service Offerings

11.4 Becton, Dickinson and Company

11.4.1 Business Overview

11.4.2 Product and Service Offerings

11.5 Daiichi Sankyo Co. Ltd.

11.5.1 Business Overview

11.5.2 Product and Service Offerings

11.6 Danaher Corporation

11.6.1 Business Overview

11.6.2 Product and Service Offerings

11.7 Hologic Inc.

11.7.1 Business Overview

11.7.2 Product and Service Offerings

11.8 Johnson & Johnson

11.8.1 Business Overview

11.8.2 Product and Service Offerings

11.9 OpGen, Inc.

11.9.1 Business Overview

11.9.2 Product and Service Offerings

11.1 F. Hoffmann La-Roche AG

11.10.1 Business Overview

11.10.2 Product and Service Offerings

Chapter 12. Appendix

12.1 Abbreviations

12.2 Sources and References

12.3 Related Reports

 

LIST OF TABLES

 

TABLE 1 ANALYSIS PERIOD OF THE STUDY

TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 5 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 6 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016 – 2023)

TABLE 7 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 8 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 9 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY REGION, $M (2016–2023)

TABLE 10 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 11 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 12 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 13 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 14 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 15 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, $M (2016–2023)

TABLE 16 U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 17 U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 18 U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 19 U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 20 U.S. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 21 CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 22 CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 23 CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 24 CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 25 CANADA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 26 MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 27 MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016-2023)

TABLE 28 MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 29 MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 30 MEXICO HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 31 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 32 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 33 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 34 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 35 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 36 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, $M (2016–2023)

TABLE 37 GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 38 GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 39 GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 40 GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 41 GERMANY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 42 FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 43 FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 44 FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 45 FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 46 FRANCE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 47 U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 48 U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 49 U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 50 U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 51 U.K. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 52 ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 53 ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 54 ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 55 ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 56 ITALY HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016 – 2023)

TABLE 57 SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 58 SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 59 SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 60 SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 61 SPAIN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 62 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 63 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 64 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 65 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 66 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 67 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, $M (2016–2023)

TABLE 68 JAPAN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 69 JAPAN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 70 JAPAN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 71 JAPAN HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 72 JAPAN. HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 73 CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 74 CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 75 CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 76 CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 77 CHINA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 78 AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 79 AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 80 AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 81 AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 82 AUSTRALIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 83 SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 84 SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 85 SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 86 SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 87 SOUTH KOREA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 88 INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 89 INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 90 INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 91 INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 92 INDIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 93 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 94 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 95 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 96 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 97 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 98 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, $M (2016–2023)

TABLE 99 BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 100 BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 101 BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 102 BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 103 BRAZIL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 104 SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 105 SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 106 SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 107 SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 108 SAUDI ARABIA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 109 SOUTH AFRICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

TABLE 110 SOUTH AFRICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

TABLE 111 SOUTH AFRICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

TABLE 112 SOUTH AFRICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

TABLE 113 SOUTH AFRICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

TABLE 114 ABBOTT LABORATORIES – AT A GLANCE

TABLE 115 ASTRAZENECA PLC - AT A GLANCE

TABLE 116 BAYER AG – AT A GLANCE

TABLE 117 BECTON, DICKINSON AND COMPANY – AT A GLANCE

TABLE 118 DAIICHI SANKYO CO., LTD. – AT A GLANCE

TABLE 119 DANAHER CORPORATION – AT A GLANCE

TABLE 120 HOLOGIC INC. - AT A GLANCE

TABLE 121 JOHNSON & JOHNSON - AT A GLANCE

TABLE 122 OPGEN, INC. – AT A GLANCE

TABLE 123 F. HOFFMANN LA-ROCHE AG – AT A GLANCE

 

LIST OF FIGURES

 

FIG 1 RESEARCH SCOPE

FIG 2 RESEARCH METHODOLOGY

FIG 3 REGIONAL SPLIT OF PRIMARY AND SECONDARY RESEARCH

FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY REGION

FIG 5 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT

FIG 6 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE

FIG 7 DATA TRIANGULATION APPROACH

FIG 8 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET SUMMARY

FIG 9 AGING POPULATION AS A PERCENTAGE OF TOTAL POPULATION

FIG 10 PORTER’S FIVE FORCES ANALYSIS

FIG 11 BARGAINING POWER OF BUYERS

FIG 12 BARGAINING POWER OF SUPPLIERS

FIG 13 INTENSITY OF RIVALRY

FIG 14 THREAT OF NEW ENTRANTS

FIG 15 THREAT OF SUBSTITUTES

FIG 16 SNAPSHOT OF GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET (2016)

FIG 17 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

FIG 18 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

FIG 19 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

FIG 20 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

FIG 21 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

FIG 22 WORLDWIDE MAJOR MARKETS FOR HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS

FIG 23 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET SNAPSHOT

FIG 24 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

FIG 25 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

FIG 26 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

FIG 27 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

FIG 28 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

FIG 29 NORTH AMERICA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, $M (2016–2023)

FIG 30 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET SNAPSHOT

FIG 31 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

FIG 32 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

FIG 33 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

FIG 34 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

FIG 35 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

FIG 36 EUROPE HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, $M (2016–2023)

FIG 37 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET SNAPSHOT

FIG 38 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

FIG 39 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

FIG 40 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

FIG 41 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

FIG 42 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

FIG 43 APAC HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, $M (2016–2023)

FIG 44 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET SNAPSHOT

FIG 45 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY PRODUCT, $M (2016–2023)

FIG 46 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY TEST TYPE, $M (2016–2023)

FIG 47 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY APPLICATION, $M (2016–2023)

FIG 48 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY INFECTION TYPE, $M (2016–2023)

FIG 49 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY END USER, $M (2016–2023)

FIG 50 LAMEA HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET, BY COUNTRY, $M (2016–2023)

FIG 51 GLOBAL HOSPITAL-ACQUIRED INFECTION DIAGNOSTICS MARKET SHARE OF KEY PLAYERS (2016)

 

Place An Order

USD 4900 USD 6400 USD 8400
  • INQUIRE BEFORE PURCHASE
Connect with our sales team
  • +91 93541 34657
  • [email protected]
Customized Report Solution

Get a bespoke market intelligence solution

  • Buy report sections that meet your requirements
  • Get the report customized as per your needs
  • Request Customized Report
Our Client Partners
Client
Share this report

Want a report tailored exactly to your business strategy?

Request Customization

Want an insight-rich discussion with the report author?

Speak to Analyst
 
We are committed to ensuring the highest level of client satisfaction
Quality Acknowledgement
Quality Acknowledgement

Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you

Unmatched Standards
Unmatched Standards

Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights

Reach Us
Reach Us Whenever You Need

With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required

Data Security
Complete Data Security

We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws

  • Make An Enquiry
  • Request Free Sample
Connect with us
Quick Links
  • Research Methodology
  • Career
  • Media Citations
  • FAQs
  • Events and Conferences
Find Help
  • How to Order
  • Privacy Policy
  • Terms & Conditions
  • Sitemap
24/7 Customer Support
  • India: +91 93541 34657
  • For business enquiries - [email protected]
  • For career enquiries - [email protected]
  • Dun-Verified
  • Paypal-Secure

©2026 P&S Intelligence. All Rights Reserved.

We use cookies to enhance your experience. By continuing to use this site you consent to our use of cookies. Privacy Policy